Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)‘s stock had its “neutral” rating reiterated by analysts at Mizuho in a note issued to investors on Tuesday. They presently have a $47.00 price objective on the specialty pharmaceutical company’s stock, up from their previous price objective of $37.80. Mizuho’s price objective points to a potential downside of 26.48% from the company’s previous close.

EGRX has been the topic of a number of other research reports. Royal Bank Of Canada reduced their target price on Eagle Pharmaceuticals from $94.00 to $78.00 and set an “outperform” rating on the stock in a report on Tuesday, May 10th. Zacks Investment Research downgraded Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Friday, July 22nd. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $98.00 target price on shares of Eagle Pharmaceuticals in a report on Thursday, April 7th. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $90.24.

Analyst Recommendations for Eagle Pharmaceuticals (NASDAQ:EGRX)

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) traded down 0.73% during mid-day trading on Tuesday, reaching $63.93. The company had a trading volume of 326,688 shares. The company has a market capitalization of $999.61 million, a price-to-earnings ratio of 327.85 and a beta of 1.16. The company has a 50 day moving average price of $63.46 and a 200 day moving average price of $48.77. Eagle Pharmaceuticals has a one year low of $33.02 and a one year high of $102.48.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/09/eagle-pharmaceuticals-inc-egrx-earns-neutral-rating-from-mizuho.html

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.09. Eagle Pharmaceuticals had a return on equity of 3.44% and a net margin of 3.45%. The company had revenue of $40.90 million for the quarter, compared to the consensus estimate of $43.55 million. During the same quarter in the previous year, the business earned ($0.53) EPS. Eagle Pharmaceuticals’s revenue was up 581.7% compared to the same quarter last year. On average, analysts anticipate that Eagle Pharmaceuticals will post $3.21 EPS for the current year.

In related news, major shareholder Proquest Investments Iv, L.P. sold 24,949 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $60.77, for a total value of $1,516,150.73. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 18.80% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the company. BlackRock Group LTD increased its stake in Eagle Pharmaceuticals by 62.9% in the first quarter. BlackRock Group LTD now owns 2,916 shares of the specialty pharmaceutical company’s stock valued at $118,000 after buying an additional 1,126 shares during the last quarter. White Pine Capital LLC acquired a new position in Eagle Pharmaceuticals during the second quarter valued at about $208,000. LaSalle Street Capital Management LLC acquired a new position in Eagle Pharmaceuticals during the second quarter valued at about $304,000. Columbus Circle Investors acquired a new position in Eagle Pharmaceuticals during the second quarter valued at about $306,000. Finally, Rhumbline Advisers boosted its position in Eagle Pharmaceuticals by 3.3% in the second quarter. Rhumbline Advisers now owns 9,295 shares of the specialty pharmaceutical company’s stock valued at $361,000 after buying an additional 297 shares during the period. Institutional investors own 95.67% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).

5 Day Chart for NASDAQ:EGRX

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.